Search Results - "Lorenzo Gerratana"

Homophilic CD44 Interactions Mediate Tumor Cell Aggregation and Polyclonal Metastasis in Patient-Derived Breast Cancer Models by Liu, Xia, Taftaf, Rokana, Kawaguchi, Madoka, Chang, Ya-Fang, Chen, Wenjing, Entenberg, David, Zhang, Youbin, Gerratana, Lorenzo, Huang, Simo, Patel, Dhwani B, Tsui, Elizabeth, Adorno-Cruz, Valery, Chirieleison, Steven M, Cao, Yue, Harney, Allison S, Patel, Shivani, Patsialou, Antonia, Shen, Yang, Avril, Stefanie, Gilmore, Hannah L, Lathia, Justin D, Abbott, Derek W, Cristofanilli, Massimo, Condeelis, John S, Liu, Huiping

“…Circulating tumor cells (CTC) seed cancer metastases; however, the underlying cellular and molecular mechanisms remain unclear. CTC clusters were less…”
Get more information

Measures of Outcome in Metastatic Breast Cancer: Insights From a Real‐World Scenario by Bonotto, Marta, Gerratana, Lorenzo, Poletto, Elena, Driol, Pamela, Giangreco, Manuela, Russo, Stefania, Minisini, Alessandro M., Andreetta, Claudia, Mansutti, Mauro, Pisa, Federica E., Fasola, Gianpiero, Puglisi, Fabio

“…No gold standard treatment exists for metastatic breast cancer (MBC). Clinical decision making is based on knowledge of prognostic and predictive factors that…”
Get full text

Platinum Salts in Patients with Breast Cancer: A Focus on Predictive Factors by Garutti, Mattia, Pelizzari, Giacomo, Bartoletti, Michele, Malfatti, Matilde Clarissa, Gerratana, Lorenzo, Tell, Gianluca, Puglisi, Fabio

“…Breast cancer (BC) is the most frequent oncologic cause of death among women and the improvement of its treatments is compelling. Platinum salts (e.g.,…”
Get full text

Association of a novel circulating tumor DNA next-generating sequencing platform with circulating tumor cells (CTCs) and CTC clusters in metastatic breast cancer by Davis, Andrew A, Zhang, Qiang, Gerratana, Lorenzo, Shah, Ami N, Zhan, Youbin, Qiang, Wenan, Finkelman, Brian S, Flaum, Lisa, Behdad, Amir, Gradishar, William J, Platanias, Leonidas C, Cristofanilli, Massimo

“…Liquid biopsies, including circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs), can be used to understand disease prognosis, tumor heterogeneity,…”
Get full text

Editorial: Cancer evolution: From biological insights to therapeutic opportunities by Davis, Andrew A., Gerratana, Lorenzo, Mina, Marco

Get full text

Therapeutic Monitoring of Palbociclib, Ribociclib, Abemaciclib, M2, M20, and Letrozole in Human Plasma: A Novel LC-MS/MS Method by Posocco, Bianca, Zanchetta, Martina, Orleni, Marco, Gagno, Sara, Montico, Marcella, Peruzzi, Elena, Roncato, Rossana, Gerratana, Lorenzo, Corsetti, Serena, Puglisi, Fabio, Toffoli, Giuseppe

“…Therapeutic drug monitoring (TDM) using cyclin-dependent kinase inhibitors (CDK4/6is) is a novel approach for optimizing treatment outcomes. Currently,…”
Get full text

Quantification of Letrozole, Palbociclib, Ribociclib, Abemaciclib, and Metabolites in Volumetric Dried Blood Spots: Development and Validation of an LC-MS/MS Method for Therapeutic Drug Monitoring by Cecchin, Eleonora, Orleni, Marco, Gagno, Sara, Montico, Marcella, Peruzzi, Elena, Roncato, Rossana, Gerratana, Lorenzo, Corsetti, Serena, Puglisi, Fabio, Toffoli, Giuseppe, Cecchin, Erika, Posocco, Bianca

“…Therapeutic drug monitoring (TDM) may be beneficial for cyclin-dependent kinase 4/6 inhibitors (CDK4/6is), such as palbociclib, ribociclib, and abemaciclib,…”
Get full text

Clinical impact of body mass index on palbociclib treatment outcomes and effect on exposure by Roncato, Rossana, Peruzzi, Elena, Gerratana, Lorenzo, Posocco, Bianca, Nuzzo, Sofia, Montico, Marcella, Orleni, Marco, Corsetti, Serena, Bartoletti, Michele, Gagno, Sara, Canil, Giovanni, De Mattia, Elena, Angelini, Jacopo, Baraldo, Massimo, Puglisi, Fabio, Cecchin, Erika, Toffoli, Giuseppe

“…The impact of body mass index (BMI) on treatment outcomes in patients with cancer is gaining increasing attention given the limited data available. The aim of…”
Get full text

APE1 and NPM1 protect cancer cells from platinum compounds cytotoxicity and their expression pattern has a prognostic value in TNBC by Malfatti, Matilde Clarissa, Gerratana, Lorenzo, Dalla, Emiliano, Isola, Miriam, Damante, Giuseppe, Di Loreto, Carla, Puglisi, Fabio, Tell, Gianluca

“…Triple negative breast cancer (TNBC) is a breast cancer subgroup characterized by a lack of hormone receptors' expression and no HER2 overexpression. These…”
Get full text

Association of ADME gene polymorphisms on toxicity to CDK4/6 inhibitors in patients with HR+ HER2- metastatic breast cancer by Peruzzi, Elena, Gerratana, Lorenzo, Montico, Marcella, Posocco, Bianca, Corsetti, Serena, Bartoletti, Michele, Gagno, Sara, Orleni, Marco, De Mattia, Elena, Baraldo, Massimo, Cecchin, Erika, Puglisi, Fabio, Toffoli, Giuseppe, Roncato, Rossana

“…A wide interindividual variability in therapeutic response to cyclin-dependent kinases 4 and 6 inhibitors (CDKis) palbociclib, ribociclib and abemaciclib,…”
Get full text

Circulating tumor cells, circulating tumor DNA, and disease characteristics in young women with metastatic breast cancer by Shah, Ami N., Carroll, Kristen J., Gerratana, Lorenzo, Lin, Chenyu, Davis, Andrew A., Zhang, Qiang, Jacob, Saya, Finkelman, Brian, Zhang, Youbin, Qiang, Wenen, D’Amico, Paolo, Reduzzi, Carolina, Gradishar, William J., Behdad, Amir, Cristofanilli, Massimo

“…Background Clinical and genomic data from patients with early-stage breast cancer suggest more aggressive disease in premenopausal women. However, the…”
Get full text

Bevacizumab or PARP-Inhibitors Maintenance Therapy for Platinum-Sensitive Recurrent Ovarian Cancer: A Network Meta-Analysis by Bartoletti, Michele, Pelizzari, Giacomo, Gerratana, Lorenzo, Bortot, Lucia, Lombardi, Davide, Nicoloso, Milena, Scalone, Simona, Giorda, Giorgio, Baldassarre, Gustavo, Sorio, Roberto, Puglisi, Fabio

“…Targeted agents such as bevacizumab (BEV) or poly (ADP-ribose) polymerase inhibitors (PARPi) which have been added as concomitant or maintenance therapies have…”
Get full text

Interplay between ESR1/PIK3CA codon variants, oncogenic pathway alterations and clinical phenotype in patients with metastatic breast cancer (MBC): comprehensive circulating tumor DNA (ctDNA) analysis by Gerratana, Lorenzo, Davis, Andrew A, Velimirovic, Marko, Clifton, Katherine, Hensing, Whitney L, Shah, Ami N, Dai, Charles S, Reduzzi, Carolina, D'Amico, Paolo, Wehbe, Firas, Medford, Arielle, Wander, Seth A, Gradishar, William J, Behdad, Amir, Puglisi, Fabio, Ma, Cynthia X, Bardia, Aditya, Cristofanilli, Massimo

“…although being central for the biology and druggability of hormone-receptor positive, HER2 negative metastatic breast cancer (MBC), ESR1 and PIK3CA mutations…”
Get full text

Cell-free DNA comparative analysis of the genomic landscape of first-line hormone receptor-positive metastatic breast cancer from the US and China by Liu, Xiaoran, Davis, Andrew A., Xie, Feng, Gui, Xinyu, Chen, Yifei, Zhang, Qiang, Gerratana, Lorenzo, Zhang, Youbin, Shah, Ami N., Behdad, Amir, Wehbe, Firas, Huang, Yong, Yu, Jianjun, Du, Pan, Jia, Shidong, Li, Huiping, Cristofanilli, Massimo

“…Purpose Meaningful comparison of mutational landscapes across ethnic groups requires the use of standardized platform technology. We have used a harmonized…”
Get full text

An Integrated Pharmacological Counselling Approach to Guide Decision-Making in the Treatment with CDK4/6 Inhibitors for Metastatic Breast Cancer by Roncato, Rossana, Gerratana, Lorenzo, Palmero, Lorenza, Gagno, Sara, Poetto, Ariana Soledad, Peruzzi, Elena, Zanchetta, Martina, Posocco, Bianca, De Mattia, Elena, Canil, Giovanni, Alberti, Martina, Orleni, Marco, Toffoli, Giuseppe, Puglisi, Fabio, Cecchin, Erika

“…A wide inter-individual variability in the therapeutic response to cyclin-dependent kinases 4 and 6 inhibitors (CDKis) has been reported. We herein present a…”
Get full text

Exploring pharmacokinetic variability of palbociclib in HR+/HER2- metastatic breast cancer: a focus on age, renal function, and drug-gene interactions by Peruzzi, Elena, Posocco, Bianca, Gerratana, Lorenzo, Nuti, Margherita, Orleni, Marco, Gagno, Sara, De Mattia, Elena, Puglisi, Fabio, Cecchin, Erika, Toffoli, Giuseppe, Roncato, Rossana

“…Palbociclib, an oral inhibitor of cyclin-dependent kinase 4 and 6, is approved for the treatment of metastatic breast cancer. This study investigated the…”
Get full text

First- and second-line treatment strategies for hormone-receptor (HR)-positive HER2-negative metastatic breast cancer: A real-world study by Basile, Debora, Gerratana, Lorenzo, Corvaja, Carla, Pelizzari, Giacomo, Franceschin, Giorgia, Bertoli, Elisa, Palmero, Lorenza, Zara, Diego, Alberti, Martina, Buriolla, Silvia, Da Ros, Lucia, Bonotto, Marta, Mansutti, Mauro, Spazzapan, Simon, Cinausero, Marika, Minisini, Alessandro Marco, Fasola, Gianpiero, Puglisi, Fabio

“…Endocrine therapy (ET) plus cyclin-dependent-kinases 4/6 inhibitors (CDK4/6i) represents the standard treatment for luminal-metastatic breast cancer (MBC)…”
Get full text

The IMPACT study: early loss of skeletal muscle mass in advanced pancreatic cancer patients by Basile, Debora, Parnofiello, Annamaria, Vitale, Maria Grazia, Cortiula, Francesco, Gerratana, Lorenzo, Fanotto, Valentina, Lisanti, Camilla, Pelizzari, Giacomo, Ongaro, Elena, Bartoletti, Michele, Garattini, Silvio Ken, Andreotti, Victoria Josephine, Bacco, Anna, Iacono, Donatella, Bonotto, Marta, Casagrande, Mariaelena, Ermacora, Paola, Puglisi, Fabio, Pella, Nicoletta, Fasola, Gianpiero, Aprile, Giuseppe, Cardellino, Giovanni G.

“…Background Pancreatic cancer (PC) patients have multiple risk factors for sarcopenia and loss of skeletal muscle mass (LSMM), which may cause greater treatment…”
Get full text

Landscape of circulating tumour DNA in metastatic breast cancer by Davis, Andrew A., Jacob, Saya, Gerratana, Lorenzo, Shah, Ami N., Wehbe, Firas, Katam, Neelima, Zhang, Qiang, Flaum, Lisa, Siziopikou, Kalliopi P., Platanias, Leonidas C., Gradishar, William J., Behdad, Amir, Cristofanilli, Massimo

“…We describe the genomic landscape of circulating tumour DNA (ctDNA) across pathological subtypes of metastatic breast cancer. 255 clinically annotated patients…”
Get full text

KRAS and ERBB-family genetic alterations affect response to PD-1 inhibitors in metastatic nonsquamous NSCLC by Cinausero, Marika, Laprovitera, Noemi, Maglio, Giovanna De, Gerratana, Lorenzo, Riefolo, Mattia, Macerelli, Marianna, Fiorentino, Michelangelo, Porcellini, Elisa, Buoro, Vanessa, Gelsomino, Francesco, Squadrilli, Anna, Fasola, Gianpiero, Negrini, Massimo, Tiseo, Marcello, Ferracin, Manuela, Ardizzoni, Andrea

“…Background: Programmed cell death 1 (PD-1) and PD-ligand 1 (PD-L1) inhibitors represent novel therapeutic options for advanced non-small cell lung cancer…”
Get full text